RT Journal Article
SR Electronic
T1 PathoSPOT genomic epidemiology reveals under-the-radar nosocomial outbreaks
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20098103
DO 10.1101/2020.05.11.20098103
A1 Ana Berbel Caban
A1 Theodore R. Pak
A1 Ajay Obla
A1 Amy C. Dupper
A1 Kieran I. Chacko
A1 Lindsey Fox
A1 Alexandra Mills
A1 Brianne Ciferri
A1 Irina Oussenko
A1 Colleen Beckford
A1 Marilyn Chung
A1 Robert Sebra
A1 Melissa Smith
A1 Sarah Conolly
A1 Gopi Patel
A1 Andrew Kasarskis
A1 Mitchell J. Sullivan
A1 Deena R. Altman
A1 Harm van Bakel
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.05.11.20098103.abstract
AB Whole genome sequencing (WGS) is increasingly used to map the spread of bacterial and viral pathogens in nosocomial settings. A limiting factor for more widespread adoption of WGS for hospital infection prevention practices is the availability of standardized tools for genomic epidemiology. Here we present the Pathogen Sequencing Phylogenomic Outbreak Toolkit (PathoSPOT), which automates integration of genomic and medical record data for rapid detection and tracing of nosocomial outbreaks. To demonstrate its capabilities we applied PathoSPOT to complete genome surveillance data of 197 MRSA bacteremia cases from two hospitals during a two-year period. PathoSPOT identified 8 clonal clusters encompassing 33 patients (16.8% of cases); none of which had been recognized by standard practices. The largest cluster corresponded to a prolonged outbreak of a hospital-associated MRSA clone among 16 adults, spanning 9 wards over a period of 21 months. Analysis of precise timeline and location data with our toolkit suggested that an initial exposure event in a single ward led to infection and long-term colonization of multiple patients, followed by transmissions to other patients during recurrent hospitalizations. Overall, we demonstrate that PathoSPOT genomic surveillance enables detection of complex transmission chains that are not readily apparent from epidemiological data and that contribute significantly to morbidity and mortality, enabling more effective intervention strategies.Competing Interest StatementRobert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai.Funding StatementThis research was supported in part by R01 AI119145 (H.v.B.), the Icahn Institute for Genomics and Data Science (A.K.), the CTSA/NCATS KL2 Program (KL2TR001435, Icahn School of Medicine at Mount Sinai; D.R.A), and the New York State Department of Health Empire Clinical Research Investigator Program (Awarded to Judith A. Aberg, Icahn School of Medicine at Mount Sinai; D.R.A.) and F30 AI122673 (T.R.P.). The Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under award numbers S10OD018522 and S10OD026880 as well as institutional funds. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study data is available at https://www.pathospot.org. https://www.pathospot.org.